|
 |
| home > pmps > autumn 2001 > the cost benefits of using ivr systems in the supply chain |
|
|
 PUBLICATIONS |
Pharmaceutical Manufacturing and Packing Sourcer
|
In the previous edition of PMPS the uses and benefits of interactive voice response (IVR) systems/services in managing the clinical supply chain process were illustrated. In this article, it is hoped to further examine the cost benefits of using such a system in the supply chain. In order to do this effectively, it is appropriate to discuss the cost factors that play a part in the implementation of IVR - either by using a service provider or by providing an in-house solution.
The need for IVR is often driven by the clinical trial supplies group in situations where: drug is in short supply; there are expiry issues; or where other degrees of complexity mean that an automated process, with a complete overview of the use of drug in the trial, is desirable to enable effective supply management. This tends to set up a dichotomy that warrants further discussion, because the budget holders (usually clinical) are frequently not the group that are perceived to make the greatest savings.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Announces Plans to Implement XcelodoseTM Technology in the Production of Early Stage Clinical Trial Materials
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today plans to implement Xcelodose technology at its formulations development facility, ApiCross Drug Delivery Technologies. Xcelodose technology is a powder micro-dosing system developed by Meridica. This technology offers a unique powder dispensing system for small-scale capsule filling and ultimately assists in conserving valuable research material as well as reducing various Preformulation activities.
More info >> |
|
 |
